Competing program . . . It is my understanding that 271 targets the 30S subunit of the bacterial ribosome. So does this:
>>Antimicrobial Activity of KBP-7072 against Acinetobacter and StenotrophomonasMaltophilia
V. Benn1, F. Yang1, Y. Wang2, Q. Liu3, M. Hong3; 1KBP BioSci.s USA, Princeton, NJ, 2KBP BioSci.s China, Jinan, Shandong, China, 3KBP BioSci.s China, Jian, Shandong, China
Background: The activity of KBP-7072, an investigational aminomethylcycline, was tested against Acinetobacter spp. and S. Maltophilia, two emerging difficult to treat aerobic bacterial pathogens in healthcare settings. Patients
with Acinetobacter colonization often have a history of prolonged hospitalization or antimicrobial therapy with antibiotics that have little or no activity
against Acinetobacter. Patients infected with S. Maltophilia often have a history of indwelling catheters, immunosuppressant therapy, broad-spectrum antibiotics, or cystic fibrosis. Antimicrobial products with activity against these pathogens would fulfill a significant emerging unmet medical need. Methods: MICs were determined at KBP Biosciences using standard agar dilution according to CLSI guidelines. Isolates were collected from 2010 to 2013 from several hospitals in China and include 68 A. baumannii isolates, 11 A. lwoffii isolates, and 14 S.
Maltophilia isolates. Results: For A. baumannii, values of KBP-7072 (MIC90 1.0 µg/mL) were 4-fold less than omadacycline and tigecycline; 16-fold less than minocycline, and >32-fold less than tetracycline and imipenem. For A. lwoffii, values of KBP-7072 (MIC90 1.0 µg/mL) were 4-fold less than omadacycline; 2-fold less than tigecycline; 8-fold less than minocycline, >32-fold less than tetracycline, and 64-fold less than imipenem. For S. Maltophilia, values of KBP-7072 (MIC90 2.0 µg/mL) were 8-fold less than omadacycline; 2-fold less than tigecycline; 2-fold less than minocycline, >16-fold less than tetracycline, and 32-fold less than
imipenem. Conclusions: In this study, the activity of KBP-7072 was notable against two emerging nosocomial bacterial species, Acinetobacter spp. and S. Maltophilia, where it had the lowest MICs of all antimicrobials tested. Activity of KBP-7072 against A. baumannii, A. lwoffii, and S. Maltophilia isolates was superior to that of omadacycline, tigecycline, minocycline, tetracycline, and imipenem. KBP-7072 is active against a broad spectrum of aerobic Gram-negative, Gram-positive, and resistant species and is undergoing further study to assess its activity against bacterial pathogens causing human disease.<<
>>Antimicrobial Activity of KBP-7072 against Community AcquiredBacterial Title: Pneumonia Pathogens
V. Benn1, F. Yang1, U. Wamg2, Q. Liu2, M. Hong2; 1KBP BioSci.s USA, Princeton,
Abstract:
NJ, 2KBP BioSci.s China, Jinan, Shandong, China
Background: The activity of KBP-7072, an investigational aminomethylcycline, was tested against recent globally-sourced bacterial isolates associated with community acquired bacterial pneumonia (CABP). Methods: MICs were determined by standard broth microdilution for typical pathogens, L. pneumophila, and M. pneumoniae, and by HEp-2 cell culture for C. pneumoniae according to CLSI guidelines. In vitro activity of KBP-7072 and comparators was tested against 1,334 recent typical bacterial isolates, and a collection of atypical species. Results: For typical CABP pathogens: Values of KBP-7072 (MIC90 =0.015 µg/mL) were 256-fold less than tetracycline and better than tigecycline for S. pneumoniae; 64-fold less than tetracycline
for MRSA and Enterococcus; and equal to tetracycline for H. influenzae and M. catarrhalis. For atypical CABP pathogens: For L. pneumophila serogroup 1,
MIC90 values were KBP-7072 (2 µg/mL), levofloxacin (=0.03 µg/mL), moxifloxacin (=0.03 µg/mL), telithromycin (0.06 µg/mL), azithromycin (0.5 µg/mL), erythromycin (1 µg/mL), tigecycline (8 µg/mL) and doxycycline (1 µg/mL). For M. pneumoniae,
MIC90 values were KBP-7072 (0.063 µg/mL), erythromycin (>256 µg/mL), levofloxacin (1 µg/mL), moxifloxacin (0.125 µg/mL), and tetracycline (0.5 µg/mL).
For C. pneumoniae, MIC90 values were KBP-7072 (0.5 µg/mL), clindamycin (>4 µg/mL), moxifloxacin (1 µg/mL), and tigecycline (0.125 µg/mL). Conclusions: KBP- 7072 is active against a broad spectrum of aerobic gram-negative and gram-positive resistant species, including MRSA, MSSA, and VRSA. Activity was notable against the most common pathogens causing CABP, particularly S. pneumoniae and M. pneumoniae, where it had the lowest MICs of all antimicrobials tested. Activity against S. aureus and M. catarrhalis was comparable to tigecycline, and greater than minocycline and tetracycline. Activity against L. pneumophila was comparable to doxycycline. KBP-7072 demonstrated good activity against C. pneumoniae with values comparable to moxifloxacin, and at least 4 to 16-fold better than clindamycin. KBP-7072 has anti-microbial activity comparable to or better than antibiotics with proven clinical efficacy in patients with CABP.<<
From the recent ASM/ESCMID confab ASM/ESCMID Poster Presentations
'T'is also in phase one. Otherwise, I know nothing. Just stumbled across it while looking for something else.
Cheers, Tuck
|
